Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ
Market Cap
$5B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
623 of 963
Rank in Industry
344 of 552
Largest Insider Buys in Sector
CRNX Stock Price History Chart
CRNX Stock Performance
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Insider Activity of Crinetics Pharmaceuticals, Inc.
Over the last 12 months, insiders at Crinetics Pharmaceuticals, Inc. have bought $0 and sold $26.42M worth of Crinetics Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Crinetics Pharmaceuticals, Inc. have bought $11.86M and sold $11.05M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $110,300 was made by Vivaldi Coelho Rogerio (director) on 2023‑06‑08.
List of Insider Buy and Sell Transactions, Crinetics Pharmaceuticals, Inc.
| 2024-12-02 | Sale | President & CEO | 10,000 0.0108% | $57.57 | $575,700 | -0.44% | ||
| 2024-11-22 | Sale | Chief Operating Officer | 501 0.0005% | $56.52 | $28,317 | +1.98% | ||
| 2024-10-03 | Sale | Chief Med and Dev Officer | 14,375 0.0194% | $54.63 | $785,306 | +7.87% | ||
| 2024-09-26 | Sale | CFO | 25,000 0.0317% | $51.11 | $1.28M | 0.00% | ||
| 2024-09-10 | Sale | Chief Scientific Officer | 1,035 0.0013% | $51.50 | $53,303 | +11.29% | ||
| 2024-08-26 | Sale | Chief Scientific Officer | 3,000 0.0038% | $53.19 | $159,570 | +4.71% | ||
| 2024-08-12 | Sale | Chief Scientific Officer | 3,000 0.0036% | $47.68 | $143,040 | +9.74% | ||
| 2024-07-25 | Sale | CFO | 19,056 0.0244% | $53.88 | $1.03M | +1.12% | ||
| 2024-07-25 | Sale | Chief Scientific Officer | 3,000 0.0038% | $53.43 | $160,290 | +1.12% | ||
| 2024-07-15 | Sale | CFO | 25,000 0.0413% | $55.00 | $1.38M | 0.00% | ||
| 2024-07-15 | Sale | Chief Operating Officer | 27,000 0.0446% | $55.00 | $1.49M | 0.00% | ||
| 2024-07-10 | Sale | Chief Scientific Officer | 3,000 0.0044% | $48.55 | $145,650 | 0.00% | ||
| 2024-07-05 | Sale | Chief Commercial Officer | 15,000 0.0199% | $44.08 | $661,200 | 0.00% | ||
| 2024-07-03 | Sale | Chief Med and Dev Officer | 14,375 0.0194% | $44.87 | $645,006 | 0.00% | ||
| 2024-06-28 | Sale | CFO | 32,129 0.0421% | $43.61 | $1.4M | 0.00% | ||
| 2024-06-26 | Sale | Chief Operating Officer | 956 0.0013% | $44.38 | $42,427 | +27.64% | ||
| 2024-06-25 | Sale | Chief Scientific Officer | 3,000 0.0038% | $45.37 | $136,110 | +19.99% | ||
| 2024-06-24 | Sale | Chief Med and Dev Officer | 9,500 0.0121% | $45.73 | $434,435 | +17.89% | ||
| 2024-06-21 | Sale | Chief Commercial Officer | 15,000 0.019% | $44.66 | $669,900 | +18.07% | ||
| 2024-06-10 | Sale | Chief Scientific Officer | 3,000 0.0037% | $43.86 | $131,580 | +18.18% |
Insider Historical Profitability
12.93%
| Wilson Marc | CFO | 111092 0.1198% | $53.89 | 0 | 8 | |
| Struthers Richard Scott | President & CEO | 100000 0.1078% | $53.89 | 2 | 14 | +35.75% |
| Betz Stephen F. | Chief Scientific Officer | 68576 0.0739% | $53.89 | 0 | 47 | |
| Knight Jeff E. | Chief Operating Officer | 51653 0.0557% | $53.89 | 0 | 5 | |
| Hassard James | Chief Commercial Officer | 29259 0.0316% | $53.89 | 0 | 2 | |
| Pizzuti Dana | Chief Med and Dev Officer | 28507 0.0307% | $53.89 | 0 | 8 | |
| Fust Matthew K | director | 18536 0.02% | $53.89 | 0 | 8 | |
| Okey Stephanie | director | 6000 0.0065% | $53.89 | 0 | 1 | |
| EDELMAN JOSEPH | 5321032 5.7377% | $53.89 | 1 | 0 | <0.0001% | |
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 5163517 5.5679% | $53.89 | 5 | 0 | +3.73% |
| Vivo Capital VIII, LLC | 10 percent owner | 298625 0.322% | $53.89 | 1 | 13 | +10.46% |
| Madan Ajay | Chief Development Officer | 176995 0.1909% | $53.89 | 0 | 2 | |
| 5AM Ventures IV, L.P. | 94489 0.1019% | $53.89 | 1 | 3 | +10.46% | |
| Krasner Alan Seth | Chief Medical Officer | 43210 0.0466% | $53.89 | 1 | 2 | +10.46% |
| Vivaldi Coelho Rogerio | director | 5000 0.0054% | $53.89 | 1 | 0 | +52.25% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| BlackRock | $254.46M | 6.89 | 5.44M | +1.7% | +$4.26M | 0.01 | |
| Driehaus Capital Management LLC | $244.64M | 6.63 | 5.23M | +3.7% | +$8.72M | 2.43 | |
| Point72 Asset Management | $231.69M | 6.28 | 4.95M | +44.85% | +$71.74M | 0.34 | |
| Fidelity Investments | $208.94M | 5.66 | 4.46M | +10.38% | +$19.65M | 0.01 | |
| Ecor1 Capital Llc | $194.51M | 5.27 | 4.16M | +106.48% | +$100.31M | 1.37 | |
| T. Rowe Price | $178.97M | 4.85 | 3.82M | +27.07% | +$38.12M | 0.02 | |
| The Vanguard Group | $167.35M | 4.53 | 3.58M | +2.07% | +$3.4M | <0.01 | |
| State Street | $152.38M | 4.13 | 3.26M | -8.66% | -$14.44M | 0.01 | |
| Paradigm BioCapital Advisors LP | $146.27M | 3.96 | 3.12M | +35.1% | +$38M | 5.31 | |
| Wellington Management Company | $139.1M | 3.77 | 2.97M | -8.43% | -$12.8M | 0.02 | |
| JENNISON ASSOCIATES LLC | $131.9M | 3.57 | 2.82M | +10.61% | +$12.65M | 0.09 | |
| T Rowe Price Investment Management Inc | $124.27M | 3.37 | 2.65M | +9.81% | +$11.11M | 0.08 | |
| Janus Henderson | $92.53M | 2.51 | 1.98M | +264.13% | +$67.12M | 0.05 | |
| First Light Asset Management | $79.12M | 2.14 | 1.69M | -14.97% | -$13.93M | 6.67 | |
| Perceptive Advisors | $69.1M | 1.87 | 1.48M | +17.58% | +$10.33M | 0.05 | |
| Geode Capital Management | $65.61M | 1.78 | 1.4M | +3.6% | +$2.28M | 0.01 | |
| Artal Group S A | $65.09M | 1.76 | 1.39M | New | +$65.09M | 0.28 | |
| OrbiMed | $64.83M | 1.76 | 1.39M | -16.93% | -$13.22M | 0.5 | |
| Cormorant Asset Management Lp | $53.83M | 1.46 | 1.15M | 0% | +$0 | 2.51 | |
| Novo Holdings A/S | $51.43M | 1.39 | 1.1M | -0.13% | -$65,534.00 | 3.59 | |
| Eventide Asset Management | $49.6M | 1.34 | 1.06M | 0% | +$0 | 0.8 | |
| Lord Abbett | $45.15M | 1.22 | 964,568 | +24.09% | +$8.77M | 0.16 | |
| Goldman Sachs | $40.45M | 1.1 | 864,107 | +32.9% | +$10.01M | 0.01 | |
| Saturn V Capital Management Llc | $30.9M | 0.84 | 660,143 | -16.13% | -$5.94M | 12.39 | |
| Ikarian Capital LLC | $30.13M | 0.82 | 643,751 | -5.38% | -$1.71M | 4.14 | |
| Dimensional Fund Advisors | $30M | 0.81 | 640,802 | -2.9% | -$894,960.40 | 0.01 | |
| Adage Capital Partners Gp L L C | $29.59M | 0.8 | 632,133 | New | +$29.59M | 0.05 | |
| Laurion Capital Management LP | $29.5M | 0.8 | 630,182 | +10.76% | +$2.86M | 0.21 | |
| Ensign Peak Advisors Inc | $29.09M | 0.79 | 621,507 | +42.65% | +$8.7M | 0.05 | |
| Morgan Stanley | $28.66M | 0.78 | 612,200 | -5.56% | -$1.69M | <0.01 | |
| Northern Trust | $28.15M | 0.76 | 601,384 | -0.17% | -$48,588.78 | 0.01 | |
| Nuveen | $25.91M | 0.7 | 553,739 | -18.47% | -$5.87M | 0.01 | |
| Bioimpact Capital Llc | $22.5M | 0.61 | 480,588 | +0.49% | +$110,190.74 | 3.64 | |
| Charles Schwab | $22.4M | 0.61 | 478,532 | +1.74% | +$381,922.79 | 0.01 | |
| Fiera Capital | $22.26M | 0.6 | 475,510 | New | +$22.26M | 0.07 | |
| Affinity Asset Advisors | $22M | 0.6 | 470,000 | +5.12% | +$1.07M | 0.33 | |
| Fisher Asset Management Llc | $20.41M | 0.55 | 436,023 | -1.2% | -$246,782.30 | 0.01 | |
| Franklin Templeton Investments | $19.34M | 0.52 | 413,209 | 0% | +$0 | 0.01 | |
| GW&K Investment Management | $18.16M | 0.49 | 388,066 | -19% | -$4.26M | 0.16 | |
| JPMorgan Chase | $17.6M | 0.48 | 375,986 | +303.83% | +$13.24M | <0.01 | |
| Bank of America | $16.72M | 0.45 | 357,142 | +3.7% | +$595,844.49 | <0.01 | |
| Vivo Capital | $16.38M | 0.44 | 350,000 | 0% | +$0 | 1.43 | |
| Integral Health Asset Management Llc | $15.21M | 0.41 | 325,000 | +62.5% | +$5.85M | 1.53 | |
| Duquesne Family Office Llc | $14.46M | 0.39 | 309,000 | New | +$14.46M | 0.39 | |
| BNY Mellon | $13.88M | 0.38 | 296,478 | -10.04% | -$1.55M | <0.01 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $13.55M | 0.37 | 289,400 | New | +$13.55M | 0.35 | |
| Millennium Management LLC | $12.41M | 0.34 | 265,011 | -29.07% | -$5.08M | 0.01 | |
| Victory Capital Management Inc | $12.04M | 0.33 | 257,145 | +39.67% | +$3.42M | 0.01 | |
| Citigroup | $11.61M | 0.32 | 248,050 | +142.45% | +$6.82M | 0.01 | |
| UBS | $11.6M | 0.31 | 247,803 | +78.96% | +$5.12M | <0.01 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.